Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the Manufacture of Clexane®
Details : The agreement aims for the for the localization of the full range of its flagship market leader product, Clexane (enoxaparin sodium), used to prevent clots from getting bigger or stopping new clots from forming.
Product Name : Clexane
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 12, 2023
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Bioventure Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Details : Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file, launch and commercialize Alvotech's portfolio of licensed biosimilars once approved, under Bioventure's exclusive strategic partnership with Alvotech in the...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 30, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Bioventure Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Biocon
Deal Size : $3,335.0 million
Deal Type : Acquisition
Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business
Details : With the closing of the deal, Biocon Biologics has full ownership of its collaboration assets, bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bPertuzumab and bGlargine 300U.
Product Name : Ogivri
Product Type : Antibody
Upfront Cash : $2,225.0 million
November 29, 2022
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Biocon
Deal Size : $3,335.0 million
Deal Type : Acquisition